Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
TP53 gene mutations, nuclear p53 accumulation, expression of waf/p21, bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme
Autore:
Kraus, JA; Wenghoefer, M; Glesmann, N; Mohr, S; Beck, M; Schmidt, MC; Schroder, R; Berweiler, U; Roggendorf, W; Diete, S; Dietzmann, K; Heuser, K; Muller, B; Fimmers, R; von Deimling, A; Schlegel, U;
Indirizzi:
Univ Bonn, Med Ctr, Dept Neurol, D-53105 Bonn, Germany Univ Bonn Bonn Germany D-53105 d Ctr, Dept Neurol, D-53105 Bonn, Germany Univ Bonn, Dept Biostat, D-5300 Bonn, Germany Univ Bonn Bonn Germany D-5300 v Bonn, Dept Biostat, D-5300 Bonn, Germany Univ Wurzburg, Dept Neurosurg, Wurzburg, Germany Univ Wurzburg Wurzburg Germany zburg, Dept Neurosurg, Wurzburg, Germany Univ Wurzburg, Dept Neuropathol, Wurzburg, Germany Univ Wurzburg Wurzburg Germany urg, Dept Neuropathol, Wurzburg, Germany Univ Madgeburg, Dept Neurol, Magdeburg, Germany Univ Madgeburg MagdeburgGermany eburg, Dept Neurol, Magdeburg, Germany Univ Madgeburg, Dept Neuropathol, Magdeburg, Germany Univ Madgeburg Magdeburg Germany , Dept Neuropathol, Magdeburg, Germany Univ Kiel, Dept Neurol, D-2300 Kiel, Germany Univ Kiel Kiel Germany D-2300 iv Kiel, Dept Neurol, D-2300 Kiel, Germany Bavaria Clin, Dept Neurol, Kreischa, Germany Bavaria Clin Kreischa Germany aria Clin, Dept Neurol, Kreischa, Germany Humboldt Univ, Dept Neuropathol, Berlin, Germany Humboldt Univ Berlin Germany dt Univ, Dept Neuropathol, Berlin, Germany Univ Bonn, Dept Neurosurg, D-5300 Bonn, Germany Univ Bonn Bonn Germany D-5300 Bonn, Dept Neurosurg, D-5300 Bonn, Germany
Titolo Testata:
JOURNAL OF NEURO-ONCOLOGY
fascicolo: 3, volume: 52, anno: 2001,
pagine: 263 - 272
SICI:
0167-594X(200105)52:3<263:TGMNPA>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
WILD-TYPE P53; LONG-TERM SURVIVAL; HUMAN BRAIN-TUMORS; RADIATION-INDUCED APOPTOSIS; THERAPY-ONCOLOGY-GROUP; HUMAN GLIOMA-CELLS; MALIGNANT GLIOMA; ASTROCYTIC TUMORS; G(1) ARREST; RADIOTHERAPY;
Keywords:
glioblastoma multiforme; long-term survival; apoptosis; tumpr suppressor gene;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
72
Recensione:
Indirizzi per estratti:
Indirizzo: Schlegel, U Univ Bonn, Med Ctr, Dept Neurol, Sigmund Freud Str 25, D-53105Bonn, Germany Univ Bonn Sigmund Freud Str 25 Bonn Germany D-53105 , Germany
Citazione:
J.A. Kraus et al., "TP53 gene mutations, nuclear p53 accumulation, expression of waf/p21, bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme", J NEURO-ONC, 52(3), 2001, pp. 263-272

Abstract

Glioblastoma multiforme (WHO grade IV; GBM) is the most common primary brain tumor with a median survival of less than one year despite multimodal treatment regimens. However, a small subgroup of GBM patients has a better clinical outcome, with a small number of patients surviving several years. Apoptosis, a genetically determined program of cell suicide, may be induced as a consequence of critical DNA damage. However, due to defects in the signaling pathways, cancer cells may escape apoptosis, despite carrying irreversible DNA damage. In the present study, we have analyzed tumors of two age-matched, equally treated groups of GBM patients with different postoperative time to tumor progression (TTP), defined as 'short-term' for TTP of less than 6 months (n = 54), and 'long-term' for TTP of more than 12 months (n =39) for alterations in apoptosis regulatory pathways: Mutations of the TP53 tumor suppressor gene and/or nuclear accumulation of its gene product p53, expression of Waf/p21, CD95 (Apo1/Fas), and Bcl-2. TP53 mutations were found in 12 out of 54 (22%) GBMs of short-term survivors and 8 out of 35 (23%) tumors of long-term survivors; the respective numbers for nuclear p53 protein accumulation were 12/53 (23%) and 10/37 (27%). Waf1/p21 expression wasfound in 13/53 (25%) tumors of short-term survivors and 9/35 (26%) GBMs oflong-term survivors. The respective numbers for Bcl-2 expression were 25/42 (60%) and 22/36 (61%) and for CD95 (Apo1/Fas) expression 20/49 (41%) and 14/36 (39%) GBMs. The percentage of alterations in genes/proteins involved in the apoptotic pathway investigated here was virtually identical in the two groups of clinically different GBM patients. Thus, our data imply that none of these alterations investigated per se has a strong impact on the overall survival of GBM patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/03/20 alle ore 00:48:48